Medaffcon’s Market Access team provides a vantage point to the entire industry
The Market Access team works actively with different actors, while helping customers in processes related to market access and market presence and in strategic planning.
Risk-Sharing Agreements
Comprehensive solutions for implementing risk-sharing models.
Confidential price agreements have become more widespread with regard to hospital medicines, while decisions on conditional reimbursement are becoming more established in the price and reimbursement processes of outpatient medicines.
Confidential agreements can be risk-sharing agreements (for example, pay for performance, conditional treatment continuation, or other contracts that reward the patient for the benefit of the treatment) or a method for sharing and managing uncertainty about the cost and effectiveness of medicines to the satisfaction of both parties. This will eventually make the medicine available to those patients who will benefit from it.
”Risk sharing agreements aim to solve the classic pharmaceutical sales dilemma of who bears the risk of effectiveness and cost effectiveness related to the purchasing and using of medicines.”
“We at Medaffcon execute risk-sharing agreements between the parties, ensuring that the agreements are operational and mutually beneficial. ”
In our service concept we:
- determine the optimal method for evaluating the medicine and, if necessary, take care of the evaluation process to ensure a medicine’s rapid commissioning decision
- design an optimal price agreement from the perspectives of both parties
- when necessary, evaluate the cost-effectiveness of the selected model and the budget impact for both parties
- are responsible for the agreement negotiations with hospitals, providing a neutral expert view on what sort of a model could be acceptable for both parties
- organize the transfer of money and goods on a “turn-key” principle, regardless of whose distribution service is used (e.g. Tamro, Oriola, Magnum)
Contact us!
A successful risk-sharing agreement:
- helps the parties to work in closer cooperation in the evaluation and implementation of a new form of treatment
- helps all parties evaluate and set the value for a new or existing form of treatment in a more precise manner
- ensures optimal treatment pricing to satisfy both parties, for example in cases where the effectiveness and benefits of new forms of treatments are still uncertain for the patient – and it enables the faster implementation and use of such treatment with a more sustainable pricing model
- enables faster market access to a new form of treatment
Typical project phases
Related articles
-
-
Heini Honkanen appointed as Medaffcon’s Market Access Lead
Heini Honkanen has been appointed as Medaffcon’s Market Access Lead. The new Market Access Team was created when the previous Price and Reimbursement and HE & Access Teams were merged.
-
Greetings from ISPOR: the use of Real World Evidence is becoming more common
Medaffconin Tanja Nieminen ja Heini Honkanen osallistuivat terveystaloustieteen tutkimukseen ja terveydenhuollon menetelmien arviointiin keskittyvään ISPOR-kongressiin marraskuussa.
